Loss of RBMS1 Promotes Anti-Tumor Immunity through Enabling PD-L1 Checkpoint Blockade in Triple-Negative Breast Cancer

Investigators reported that the RNA binding protein RBMS1 was prevalent among immune-cold triple-negative breast cancer (TNBC) and provided a new immunotherapeutic strategy against TNBC by targeting RBMS1.